Agios Pharmaceuticals, Inc. AGIO
Institutional shares held
59.9 Million
270K
calls
332K
puts
Total value of holdings
$2.01B
$9.07M
calls
$11.1M
puts
Market Cap
$1.84B
54,818,000
Shares Out.
Institutional ownership
109.3%
# of Institutions
244
We take great care to ensure that the data presented and summarized in this overview for AGIOS PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AGIO
View all-
Farallon Capital Management LLC San Francisco, CA5.67MShares$191 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$189 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$163 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.52MShares$118 Million2.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.42MShares$81.5 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY2.26MShares$76.1 Million1.05% of portfolio
-
State Street Corp Boston, MA2.15MShares$72.3 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.01MShares$67.6 Million0.81% of portfolio
-
Macquarie Group LTD Australia, C31.68MShares$56.6 Million0.06% of portfolio
-
Jefferies Financial Group Inc. New York, NY1.5MShares$50.4 Million0.31% of portfolio
Latest Institutional Activity in AGIO
Top Purchases
Top Sells
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AGIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,272
-29.47%
|
$77,248
$34.39 P/Share
|
|
Feb 01
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,896
+47.22%
|
-
|
|
Jan 06
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,804
-12.92%
|
$89,728
$32.18 P/Share
|
|
Jan 03
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,476
+28.08%
|
-
|
|
Dec 11
2024
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.28%
|
$9,200
$46.28 P/Share
|
|
Dec 11
2024
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.26%
|
$3,600
$18.09 P/Share
|
|
Nov 08
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
772
-48.71%
|
$43,232
$56.09 P/Share
|
|
Nov 08
2024
|
Rahul D. Ballal Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.28%
|
$580,000
$58.34 P/Share
|
|
Nov 08
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.72%
|
$250,000
$25.99 P/Share
|
|
Nov 07
2024
|
Rahul D. Ballal Director |
SELL
Open market or private sale
|
Direct |
10,000
-32.07%
|
$530,000
$53.87 P/Share
|
|
Nov 07
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.72%
|
$250,000
$25.99 P/Share
|
|
Nov 07
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,752
-35.25%
|
$1,131,104
$52.28 P/Share
|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,542
-11.2%
|
$124,558
$49.03 P/Share
|
|
Sep 26
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,473
+24.77%
|
-
|
|
Aug 11
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 11
2024
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+22.36%
|
-
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,091
-12.34%
|
$465,822
$42.75 P/Share
|
|
Aug 08
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+20.16%
|
-
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,705
-7.81%
|
$159,315
$43.85 P/Share
|
|
Jul 01
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,375
+15.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
315K
Shares
From
15
Insiders
| Exercise of conversion of derivative security | 315K shares |
|---|
Sell / Disposition
247K
Shares
From
12
Insiders
| Open market or private sale | 243K shares |
|---|---|
| Bona fide gift | 3.56K shares |